These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 29983236)

  • 1. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.
    Siegler AJ; Mouhanna F; Giler RM; Weiss K; Pembleton E; Guest J; Jones J; Castel A; Yeung H; Kramer M; McCallister S; Sullivan PS
    Ann Epidemiol; 2018 Dec; 28(12):841-849. PubMed ID: 29983236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018.
    Siegler AJ; Mehta CC; Mouhanna F; Giler RM; Castel A; Pembleton E; Jaggi C; Jones J; Kramer MR; McGuinness P; McCallister S; Sullivan PS
    Ann Epidemiol; 2020 May; 45():24-31.e3. PubMed ID: 32336655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-area spatial-temporal changes in pre-exposure prophylaxis (PrEP) use in the general population and among men who have sex with men in the United States between 2012 and 2018.
    Mouhanna F; Castel AD; Sullivan PS; Kuo I; Hoffman HJ; Siegler AJ; Jones JS; Mera Giler R; McGuinness P; Kramer MR
    Ann Epidemiol; 2020 Sep; 49():1-7. PubMed ID: 32951802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-exposure prophylaxis for preventing acquisition of HIV: A cross-sectional study of patients, prescribers, uptake, and spending in the United States, 2015-2016.
    Chan SS; Chappel AR; Maddox KEJ; Hoover KW; Huang YA; Zhu W; Cohen SM; Klein PW; De Lew N
    PLoS Med; 2020 Apr; 17(4):e1003072. PubMed ID: 32275654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
    Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN
    Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of national commissioning of pre-exposure prophylaxis (PrEP) on equity of access in England: a PrEP-to-need ratio investigation.
    Coukan F; Sullivan A; Mitchell H; Jaffer S; Williams A; Saunders J; Atchison C; Ward H
    Sex Transm Infect; 2024 Apr; 100(3):166-172. PubMed ID: 38508708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010-2014.
    Wu H; Mendoza MC; Huang YA; Hayes T; Smith DK; Hoover KW
    Clin Infect Dis; 2017 Jan; 64(2):144-149. PubMed ID: 27986691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional Disparities in Qualified Health Plans' Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United States.
    McManus KA; Powers S; Killelea A; Tello-Trillo S; Rogawski McQuade E
    JAMA Netw Open; 2020 Jun; 3(6):e207445. PubMed ID: 32492164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HIV Pre-exposure Prophylaxis (PrEP) Cascade at NYC Sexual Health Clinics: Navigation Is the Key to Uptake.
    Pathela P; Jamison K; Blank S; Daskalakis D; Hedberg T; Borges C
    J Acquir Immune Defic Syndr; 2020 Apr; 83(4):357-364. PubMed ID: 31904700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early experience of implementing a national HIV pre-exposure prophylaxis service in Wales, United Kingdom 2017.
    Fina L; Phillips AL; Jones AT; Couzens ZM; Drayton R; Thomas DR; Shankar AG
    Sex Health; 2019 Feb; 16(1):56-62. PubMed ID: 30501846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress and pitfalls in measuring HIV preexposure prophylaxis coverage in the United States.
    Rosenberg ES; Marcus JL
    Ann Epidemiol; 2018 Dec; 28(12):830-832. PubMed ID: 30224292
    [No Abstract]   [Full Text] [Related]  

  • 15. Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions.
    Sullivan PS; Mouhanna F; Mera R; Pembleton E; Castel AD; Jaggi C; Jones J; Kramer MR; McGuinness P; McCallister S; Siegler AJ
    Ann Epidemiol; 2020 Apr; 44():16-30. PubMed ID: 32088073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to do it: setting up a PrEP service in an integrated sexual reproductive health service setting.
    Knapper C; Birley H; Couzens Z; Jones AT; Parker I
    Sex Transm Infect; 2018 Aug; 94(5):327-330. PubMed ID: 29950377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review.
    Mayer KH; Agwu A; Malebranche D
    Adv Ther; 2020 May; 37(5):1778-1811. PubMed ID: 32232664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MOVING FORWARD WITH PrEP. THE BASICS OF PrEP.
    Highleyman L
    Posit Aware; 2015; 27(5):2-3. PubMed ID: 26714333
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.
    Trang TP; Dong BJ; Kojima N; Klausner JD
    Expert Opin Drug Saf; 2016 Sep; 15(9):1287-94. PubMed ID: 27391203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.